What amount sold does Cytogel Pharma, LLC report in Form D filings?

The latest linked filings report $8.9M sold across 10 identified offering(s). 1 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Cytogel Pharma, LLC's most recent SEC filing?

Cytogel Pharma, LLC's most recent Form D filing was on 2026-03-26.

What type of securities does Cytogel Pharma, LLC offer?

Cytogel Pharma, LLC's SEC Form D filings indicate equity offerings.

Cytogel Pharma, LLC

CIK: 0001491841·Pharmaceuticals·DARIEN, CT·Limited Liability Company

Reported Sold

$8,913,779

Total Filings

Identified Offerings

Last Filed

Mar 26, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 1 unlinked amendment excluded.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Mar 26, 2026Form D/A — Amendment

Reported sold: $0 · Target: $16,000,000

Rule 506(b)·0 investors

Changed: Sales commissions, Finders fees, Non-accredited investors

Dec 23, 2025Form D/A — Amendment

Reported sold: $250,000 · Target: $1,000,000

No verified predecessor available.

Rule 506(b)·3 investors

Dec 22, 2025Form D — New notice

Reported sold: $0 · Target: $16,000,000

Rule 506(b)·0 investors

Oct 11, 2024Form D/A — Amendment

Reported sold: $1,763,884 · Target: $2,193,276

Rule 506(b)·18 investors

Changed: Reported amount sold, Reported investors

Jul 28, 2023Form D — New notice

Reported sold: $1,653,884 · Target: $2,193,276

Rule 506(b)·15 investors

Jul 12, 2022Form D — New notice

Reported sold: $50,000 · Target: $1,500,000

Rule 506(b)·1 investor

May 21, 2021Form D/A — Amendment

Reported sold: $956,905 · Target: $25,000,000

Rule 506(b)·12 investors

Changed: Reported amount sold, Reported investors

Mar 16, 2021Form D/A — Amendment

Reported sold: $675,355 · Target: $25,000,000

Rule 506(b)·10 investors

Changed: Reported amount sold, Reported investors

Mar 23, 2020Form D/A — Amendment

Reported sold: $575,000 · Target: $25,000,000

Rule 506(b)·3 investors

Changed: Reported amount sold, Reported investors, Sales commissions

Sep 30, 2019Form D — New notice

Reported sold: $500,000 · Target: $25,000,000

Rule 506(b)·1 investor

Mar 12, 2019Form D — New notice

Reported sold: $100,000 · Target: $200,000

Rule 506(b)·3 investors

May 31, 2018Form D — New notice

Reported sold: $161,800 · Target: $3,000,000

Rule 506(b)·5 investors

Jan 7, 2015Form D — New notice

Reported sold: $2,691,190 · Target: $8,000,000

Rule 506(b)·10 investors

Mar 20, 2014Form D — New notice

Reported sold: $240,000 · Target: $1,110,000

Rule 506(b)·2 investors

Jul 12, 2013Form D/A — Amendment

Reported sold: $750,000 · Target: $2,000,000

Rule 506·6 investors

Changed: Reported amount sold, Offering target, Reported investors

Feb 12, 2013Form D — New notice

Reported sold: $15,475 · Target: $700,000

Rule 506·1 investor

May 17, 2010Form D — New notice

Reported sold: $2,200,000 · Target: $2,200,000

Rule 506·7 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$2,120,000

Amendment Rate

41%

Latest reported sold across 10 identified offerings

$8,913,779

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

1 unlinked amendment excluded.

Key People

Theodore Maione

Executive Officer

Appears on 15 filings

Frederick W. Telling

Executive Officer, Director

Appears on 13 filings

Cassandra Klimp

Director

Appears on 12 filings

C. Dean Maglaris

Executive Officer, Director

Appears on 10 filings

Joseph J. Rucci

Related Person

Appears on 9 filings

Steven Chrust

Related Person

Appears on 8 filings

C. Dean Maglaris

Related Person

Appears on 5 filings

Jerry P. Leamon

Director

Appears on 5 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Mar 26, 2026	Amendment	$16,000,000	$0	0
Dec 23, 2025	Amendment	$1,000,000	$250,000	3
Dec 22, 2025	New	$16,000,000	$0	0
Oct 11, 2024	Amendment	$2,193,276	$1,763,884	18
Jul 28, 2023	New	$2,193,276	$1,653,884	15
Jul 12, 2022	New	$1,500,000	$50,000	1
May 21, 2021	Amendment	$25,000,000	$956,905	12
Mar 16, 2021	Amendment	$25,000,000	$675,355	10
Mar 23, 2020	Amendment	$25,000,000	$575,000	3
Sep 30, 2019	New	$25,000,000	$500,000	1
Mar 12, 2019	New	$200,000	$100,000	3
May 31, 2018	New	$3,000,000	$161,800	5
Jan 7, 2015	New	$8,000,000	$2,691,190	10
Mar 20, 2014	New	$1,110,000	$240,000	2
Jul 12, 2013	Amendment	$2,000,000	$750,000	6
Feb 12, 2013	New	$700,000	$15,475	1
May 17, 2010	New	$2,200,000	$2,200,000	7

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Thetis Pharmaceuticals LLC

Pharmaceuticals

Offering target: $1,000,000

Filed Oct 13, 2026